The Committee takes these nominations extremely seriously, so we are pleased to have strong nominees before us today.
James Lankford
The Public Record
James Paul Lankford is an American politician serving as the junior United States senator from Oklahoma since January 2015. A member of the Republican Party, Lankford has focused on issues such as healthcare, government spending, and religious freedom during his time in office. He previously served as a member of the U.S. House of Representatives from 2011 to 2015, representing Oklahoma's 5th congressional district.
If there are additional authorities that are needed on that, we just need to know
The statute that governs the Federal workforce and labor-management disputes and all is about 38 years old now.
I think it is very important that those department heads are able to respond to those threats.
It probably could be updated into the 21st Century, and I would encourage Congress to maybe consider that.
Well, that is why we started it early because you know my next question on that is the disposal process.
It is very difficult for Members of the Senate or Members of the House to get information from agencies about recommendations for statutory changes that are needed.
The challenge every judge has, regardless of their role, is setting aside your own biases.
Obviously if we have an area where we are not authorizing or allowing or transferring, we do not want it to be more expensive than actually maintaining it.
I ask unanimous consent that the Senate recess as under the previous order. ____________________
I ask unanimous consent that the Senate be in a period of morning business, with Senators permitted to speak therein for up to 10 minutes each. The PRESIDING OFFICER. Is there objection? Without objection, it is so ordered. The Senator…
I am concerned that the FDA has a requirement and that they are trying to fulfill that requirement to be able to get the drug to market, but that it may inadvertently doom some child or some adult to be stuck in a situation where they are…
How do you all deal with the moral issues and the ethical issues of leaving those that are getting the placebo--knowing that they are in a terminal status, as opposed to trying to shift them over?
I would be glad to be able to get that, because that may broaden out and accelerate some of the process as well.
So the 45 minutes is not just completing the form. It is gathering information.
I have people in this study that are terminal, and that you are allowing the study to be able to go through, to the end, when you see an obvious effect.
When the first level is done and patients hear the stories--or people that are not patients hear the stories--this seems to be effective, but then there is the pause to say, 'We are going to go through multiple other areas.'
It has obviously been extremely important to this subcommittee and to myself as well, that we continue to promote the value of religious freedom around the world.





